Month: March 2022

Isoray to Participate in the Oppenheimer 32nd Annual Healthcare Conference

A live webcast of the virtual fireside chat will be available on Isoray’s Investor Relations section of the Company’s website at

Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray’s Cesium-131

The published article on the study, Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution, was authored by Joshua L. Rodríguez-López, MD, Ankur K. Patel, MD, Ronald M. Benoit, MD, Sushil Beriwal, MD, Ryan P. Smith, MD, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Scroll to top